An overview of compounded tirzepatide and the regulatory questions consumers should understand.
What it is
Compounded tirzepatide is a pharmacy-prepared product made under compounding laws for a prescription. It is not the same regulatory product as FDA-approved tirzepatide brands.
Current regulatory environment
FDA ended shortage-based enforcement discretion and in 2026 proposed excluding tirzepatide, semaglutide and liraglutide from the 503B bulks list. The legal conditions for compounding therefore matter.
What to verify
- The dispensing pharmacy
- The prescription and clinician
- The formulation
- Storage and administration instructions
- The reason a compounded product is being used
Sources & verification
We use primary sources for time-sensitive commercial and regulatory claims.
- FDA — Compounding and the FDA: Questions and Answers
- FDA — Concerns with unapproved GLP-1 drugs used for weight loss
- FDA — Proposed exclusion of semaglutide, tirzepatide and liraglutide from 503B bulks list
Last reviewed: August 19, 2026